Brokerages Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) PT at $16.88

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has been assigned an average recommendation of “Hold” from the six brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $16.8750.

Several research analysts have weighed in on HCM shares. Jefferies Financial Group raised shares of HUTCHMED to a “strong-buy” rating in a research note on Monday, January 19th. Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a research note on Thursday, January 22nd. Wall Street Zen lowered shares of HUTCHMED from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Finally, Bank of America dropped their target price on shares of HUTCHMED from $21.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, March 10th.

Institutional Investors Weigh In On HUTCHMED

Institutional investors have recently modified their holdings of the company. Jane Street Group LLC grew its position in HUTCHMED by 128.0% in the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after acquiring an additional 124,771 shares in the last quarter. UBS Group AG lifted its position in shares of HUTCHMED by 112.8% during the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after purchasing an additional 72,614 shares in the last quarter. Amundi boosted its stake in shares of HUTCHMED by 41.9% in the third quarter. Amundi now owns 223,330 shares of the company’s stock valued at $3,620,000 after purchasing an additional 65,898 shares during the period. M&G PLC boosted its stake in shares of HUTCHMED by 26.7% in the fourth quarter. M&G PLC now owns 259,033 shares of the company’s stock valued at $3,367,000 after purchasing an additional 54,601 shares during the period. Finally, Tema Etfs LLC acquired a new position in shares of HUTCHMED in the second quarter valued at approximately $641,000. 8.82% of the stock is owned by institutional investors and hedge funds.

HUTCHMED Stock Performance

HCM stock opened at $13.81 on Friday. HUTCHMED has a 52-week low of $11.51 and a 52-week high of $19.50. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.96 and a quick ratio of 4.83. The business has a fifty day moving average of $14.64 and a two-hundred day moving average of $14.80.

HUTCHMED (NASDAQ:HCM) last announced its quarterly earnings results on Friday, March 6th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $2.50 by ($2.49). The firm had revenue of $135.42 million during the quarter, compared to analyst estimates of $290.50 million. Analysts predict that HUTCHMED will post 0.16 EPS for the current fiscal year.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.